Sonnet BioTherapeutics Holdings (SONN) just unveiled an update.
Promising results from the Phase 1b trial of SON-080 for chemotherapy-induced peripheral neuropathy (CIPN) have sparked interest in advancing to Phase 2, particularly for treating Diabetic Peripheral Neuropathy (DPN). SON-080 demonstrated tolerability and potential symptom improvement without pro-inflammatory cytokine responses. With conventional treatments often ineffective, SON-080’s progress represents a significant stride in addressing the unmet need for effective neuropathy therapies. The company is now seeking partnerships to initiate a Phase 2 trial, highlighting SON-080’s promise in improving the quality of life for patients with peripheral neuropathy.
Find detailed analytics on SONN stock on TipRanks’ Stock Analysis page.
